×

Presenter

Steve Rozzo

Stephen Rozzo is currently Senior Director of Dermatology Medical Affairs at Sun Pharmaceuticals in Princeton, NJ. His current focus is on tildrakizumab, a humanized anti-interleukin 23 monoclonal antibody. He has previous research experience at University of Colorado Health Sciences Center and National Jewish Hospital in Denver, CO.



Presentations by Steve Rozzo
Safety and Efficacy of Tildrakizumab, a High-Affinity Anti-Interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis
Safety and Efficacy of Tildrakizumab, a High-Affinity Anti-Interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis
Philip J Mease, Saima Chohan, Ferran J García Fructuoso, Alice B Gottlieb, Richard C Chou
Tildrakizumab Efficacy by Metabolic Syndrome Status in Psoriasis: 3-Year Data from the Phase 3 reSURFACE 1 Study
Tildrakizumab Efficacy by Metabolic Syndrome Status in Psoriasis: 3-Year Data from the Phase 3 reSURFACE 1 Study
Mark G Lebwohl, Nehal N Mehta, Alice B Gottlieb, Alan M Mendelsohn, Jeff Parno
Tildrakizumab Efficacy on Psoriasis in Patients with Psoriatic Arthritis-An Analysis from a Phase 2 Study
Tildrakizumab Efficacy on Psoriasis in Patients with Psoriatic Arthritis-An Analysis from a Phase 2 Study
Alice B Gottlieb, Rocco  Ballerini, Richard  C Chou, Stephen J Rozzo, Alan M Mendelsohn


No presentations found for today.